Biological Characterization of Human Autologous Pericardium Treated with the Ozaki Procedure for Aortic Valve Reconstruction.
Ozaki procedure
aortic valve reconstruction
cardiac surgery
glutaraldehyde treatment
human autologous pericardium
re-endothelialization
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
20
07
2021
revised:
25
08
2021
accepted:
27
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
The Ozaki procedure is an innovative surgical technique aiming at reconstructing aortic valves with human autologous pericardium. Even if this procedure is widely used, a comprehensive biological characterization of the glutaraldehyde (GA)-fixed pericardial tissue is still missing. Morphological analysis was performed to assess the general organization of pericardium subjected to the Ozaki procedure (post-Ozaki) in comparison to native tissue (pre-Ozaki). The effect of GA treatment on cell viability and nuclear morphology was then investigated in whole biopsies and a cytotoxicity assay was executed to assess the biocompatibility of pericardium. Finally, human umbilical vein endothelial cells were seeded on post-Ozaki samples to evaluate the influence of GA in modulating the endothelialization ability in vitro and the production of pro-inflammatory mediators. The Ozaki procedure alters the arrangement of collagen and elastic fibers in the extracellular matrix and results in a significant reduction in cell viability compared to native tissue. GA treatment, however, is not cytotoxic to murine fibroblasts as compared to a commercially available bovine pericardium membrane. In addition, in in vitro experiments of endothelial cell adhesion, no difference in the inflammatory mediators with respect to the commercial patch was found. The Ozaki procedure, despite alteration of ECM organization and cell devitalization, allows for the establishment of a noncytotoxic environment in which endothelial cell repopulation occurs.
Sections du résumé
BACKGROUND
BACKGROUND
The Ozaki procedure is an innovative surgical technique aiming at reconstructing aortic valves with human autologous pericardium. Even if this procedure is widely used, a comprehensive biological characterization of the glutaraldehyde (GA)-fixed pericardial tissue is still missing.
METHODS
METHODS
Morphological analysis was performed to assess the general organization of pericardium subjected to the Ozaki procedure (post-Ozaki) in comparison to native tissue (pre-Ozaki). The effect of GA treatment on cell viability and nuclear morphology was then investigated in whole biopsies and a cytotoxicity assay was executed to assess the biocompatibility of pericardium. Finally, human umbilical vein endothelial cells were seeded on post-Ozaki samples to evaluate the influence of GA in modulating the endothelialization ability in vitro and the production of pro-inflammatory mediators.
RESULTS
RESULTS
The Ozaki procedure alters the arrangement of collagen and elastic fibers in the extracellular matrix and results in a significant reduction in cell viability compared to native tissue. GA treatment, however, is not cytotoxic to murine fibroblasts as compared to a commercially available bovine pericardium membrane. In addition, in in vitro experiments of endothelial cell adhesion, no difference in the inflammatory mediators with respect to the commercial patch was found.
CONCLUSIONS
CONCLUSIONS
The Ozaki procedure, despite alteration of ECM organization and cell devitalization, allows for the establishment of a noncytotoxic environment in which endothelial cell repopulation occurs.
Identifiants
pubmed: 34501402
pii: jcm10173954
doi: 10.3390/jcm10173954
pmc: PMC8432048
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Proc Natl Acad Sci U S A. 1981 Jan;78(1):363-7
pubmed: 6941251
Expert Opin Biol Ther. 2004 Dec;4(12):1971-85
pubmed: 15571459
Biomedicines. 2021 Jul 15;9(7):
pubmed: 34356888
Biotechnol Prog. 2007 Jan-Feb;23(1):210-6
pubmed: 17269690
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Ann Surg. 1970 Jun;171(6):939-47
pubmed: 5420935
Stem Cells Dev. 2012 Mar 20;21(5):767-77
pubmed: 21521013
J Thorac Cardiovasc Surg. 1995 Aug;110(2):511-6
pubmed: 7637369
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1396-404
pubmed: 16516857
J Hematol Oncol. 2020 Jul 13;13(1):91
pubmed: 32660524
Curr Protoc Pharmacol. 2004 Sep 1;Chapter 12:Unit 12.8
pubmed: 22294120
Toxicol Lett. 2006 Jan 5;160(2):171-7
pubmed: 16111842
Int J Mol Sci. 2020 Jul 11;21(14):
pubmed: 32664529
Med Sci Monit. 2019 Aug 28;25:6462-6473
pubmed: 31461437
J Mater Sci Mater Med. 2018 Nov 3;29(11):172
pubmed: 30392024
J Immunol. 2001 Sep 15;167(6):3435-42
pubmed: 11544336
Tissue Eng Part B Rev. 2018 Jun;24(3):240-253
pubmed: 29327671
J Pharmacol Toxicol Methods. 2016 May-Jun;79:15-22
pubmed: 26780674
J Thorac Cardiovasc Surg. 1964 Jun;47:693-701
pubmed: 14174962
Braz J Cardiovasc Surg. 2021 Feb 01;36(1):125-129
pubmed: 33355794
Mater Sci Eng C Mater Biol Appl. 2013 Jan 1;33(1):85-90
pubmed: 25428047
Indian J Thorac Cardiovasc Surg. 2019 Jan;35(1):41-50
pubmed: 33060968
J Biomed Mater Res B Appl Biomater. 2014 Apr;102(3):574-82
pubmed: 24123957
Ann Thorac Cardiovasc Surg. 2012;18(5):434-7
pubmed: 22572232
Turk Gogus Kalp Damar Cerrahisi Derg. 2019 Oct 23;27(4):454
pubmed: 32082907
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1739-1745.e1
pubmed: 24930607
Sci Rep. 2019 Nov 13;9(1):16688
pubmed: 31723198
J Thorac Cardiovasc Surg. 2018 Jun;155(6):2379-2387
pubmed: 29567131
J Biomater Appl. 2019 Sep;34(3):451-459
pubmed: 31195917
Interact Cardiovasc Thorac Surg. 2011 Apr;12(4):550-3
pubmed: 21273254
Ann Thorac Surg. 2005 Mar;79(3):1072-80
pubmed: 15734452
Aesthetic Plast Surg. 2008 Jan;32(1):155-8; discussion 159-61
pubmed: 17805922
Artif Organs. 2003 Aug;27(8):692-4
pubmed: 12911342
Scand J Immunol. 2004 Dec;60(6):566-73
pubmed: 15584967
J Mater Sci Mater Med. 1999 Oct-Nov;10(10/11):683-8
pubmed: 15347986
Biomaterials. 2005 May;26(13):1457-66
pubmed: 15522747
Biomaterials. 2000 Nov;21(22):2323-30
pubmed: 11026639
Int J Mol Sci. 2020 Feb 20;21(4):
pubmed: 32093391
Biomacromolecules. 2018 Apr 9;19(4):1234-1244
pubmed: 29539266